OM1, Inc.

💡How can real-world data accelerate drug development? Join our upcoming webinar, where you'll learn from successful real-world case examples on how to: ✔️ Design fit-for-purpose RWE studies for regulatory and clinical impact ✔️ Reduce burden on sites and patients with data collection models ✔️ Derive new endpoints using AI and unstructured data 📅 Save your seat: https://okt.to/bNHgBw DIA Nancy A. Dreyer Eric Schrock #DrugDevelopment #MarketAccess #ClinicalResearch #LifeSciences #Pharma #DataAutomation

💡Last week, we shared the kinds of questions AI and enhanced real-world data help answer for commercial teams. This week, we're sharing what you can do with these insights. ✅ Profile patients and the physicians they see to uncover knowledge gaps and opportunities for outreach ✅ Heatmap potential patients and their physicians to identify ‘clusters’ remaining undiagnosed or untreated ✅ Implement PhenOM profile-based screening in health systems at the point of care or in direct-to-patient outreach 📍Watch the full webinar to learn how you can connect with the right patients at the right time: https://okt.to/maMXKe Fierce Pharma Joseph Zabinski, Ph.D., M.E.M. Kathryn Starzyk #FiercePharma #AI #MachineLearning #CommercialPharma

Excited to see the impact of real-world data in action. This collaboration with Nalu Medical, Inc. highlights how linking diverse data sources—like EHRs, claims, and device data—can provide powerful insights into patient outcomes and care patterns. Proud of the OM1 team for driving innovation in healthcare research! Carl D. Marci, M.D.

We’re excited to announce our participation in the World Orphan Drug Congress in Boston from 22nd-24th April. Our US Rare Disease team, including Kate Hanman, Sarah Neubert and Caitlin Duffy would love to connect. Visit us at Booth 419 in the exhibition hall. Join us for our fireside chat on "Beyond the Buzz: Practical Applications of AI to Maximize Real-World Data" held on Wednesday 23rd April from 11:45 to 12:05 (ET) in Theater 3, Hall C. Dr. Joseph Zabinski, Ph.D., M.E.M. (VP and Head of Commercial Strategy & AI at OM1, Inc.) and Kate Hanman (our US Head of Rare Diseases), will explore using AI to address challenges like diagnostic coding and small patient numbers in the rare disease community. We look forward to seeing you there! #WODCUSA #RareDiseases #AI

🎙️🌟 NEW Behind the Insights: Decoding Treatment-Resistant Depression with Carl D. Marci, M.D. 🔎 What you'll learn in this episode: ✅ Why traditional methods often miss TRD patients ✅ How to bring “unseen” patients to light ✅ How unstructured clinical notes can help highlight “psychiatrist-attested TRD” 📍Watch the full episode here: https://okt.to/neCWK7 #AI #MentalHealth #TreatmentResistantDepression #TRD #Depression

🎉 We just hit 25,000 followers, and we couldn’t have done it without you! Your support, curiosity, and passion for advancing healthcare through real-world data and AI drive everything we do at OM1. Thank you for being part of our community! As we grow, we’d love to hear from you: 💬 What’s one challenge your organization is facing where real-world data could make a difference? Tell us in the comments. Here’s to continuing the journey together 💙

💡 Can your study handle millions of patients and hundreds of variables—without going over budget? Here’s a few facts from a recent large-scale observational research study conducted with Aspen ⬇️ ✅ Real-world data from 60+ facilities ✅ Over 1 million patients represented ✅ 300+ clinical variables collected for each subject ✅ 70+ Net Promoter Score ✅ Cost per subject in the $$ range, not $$$$ Ready to see this kind of scale in your own studies? Watch the latest episode of Behind the Insights where Rich Gliklich shares how a leading biopharma company achieved this with the help of Aspen's automated evidence generation. 📍Watch the full episode 👉 https://okt.to/sxmi4a

💡 What questions can AI and enhanced real-world data help answer for commercial teams? ✅ Identify overlooked patient populations ✅ Uncover gaps between clinical guidelines and actual practice ✅ Enhance market positioning and messaging ✅ Improve patient access and engagement ✅ And so many more! 📍Watch the recording from our recent webinar here 👉 https://okt.to/5MihVI Fierce Pharma Joseph Zabinski, Ph.D., M.E.M. Kathryn Starzyk #CommercialPharma #FiercePharma #AI #MachineLearning

💡 Structured data often falls short in capturing the full journey of patient progress. Bring richer, real-time insights from unstructured data to the surface for a more complete view into patient outcomes that support more responsive, patient-centered research and strengthen evidence for treatment effectiveness. 📖 See how it's possible in this blog: https://okt.to/tLH73y #PHQ9 #Depression #MentalHealth #AI #MachineLearning

To drive meaningful impact in #drugdevelopment, researchers need scalable, high-quality data that is fit-for-purpose. Our latest blog explores how Aspen supports faster decision-making, deeper insights, and more effective evidence generation. 📖 Learn about the technology changing the research paradigm: https://okt.to/RJu9nx #Regulatory #Pharma #MedicalAffairs #ClinicalData #RealWorldEvidence #DataNetworks #OM1Aspen